LIVZON PHARMAC. GRP H YC1 Asset Resilience Ratio

Latest as of March 2026: 2.93%

LIVZON PHARMAC. GRP H YC1 asset resilience ratio. LIVZON PHARMAC. GRP H YC1 (LP6) has an Asset Resilience Ratio of 2.93% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LIVZON PHARMAC. GRP H YC1 (LP6) defensive interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€707.99 Million

≈ $827.72 Million USD Cash + Short-term Investments

Total Assets

€24.19 Billion

≈ $28.29 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of LIVZON PHARMAC. GRP H YC1 (2021–2025)

Asset resilience ratio of LIVZON PHARMAC. GRP H YC1 from 2021 to 2025. This chart shows how LIVZON PHARMAC. GRP H YC1's Asset Resilience Ratio has changed over time. Read LP6 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down LIVZON PHARMAC. GRP H YC1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see LIVZON PHARMAC. GRP H YC1 balance sheet assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€707.99 Million	2.93%
Total Liquid Assets	€707.99 Million	2.93%

Asset Resilience Insights

Limited Liquidity: LIVZON PHARMAC. GRP H YC1 maintains only 2.93% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

LIVZON PHARMAC. GRP H YC1 Industry Peers by Asset Resilience Ratio

Compare LIVZON PHARMAC. GRP H YC1's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Viatris Inc NASDAQ:VTRS	Drug Manufacturers - Specialty & Generic	1.48%
Tianjin Zhongxin Pharmaceutical Group Corp Ltd SHG:600329	Drug Manufacturers - Specialty & Generic	5.92%
Walvax BioTech SHE:300142	Drug Manufacturers - Specialty & Generic	2.20%
Curaleaf Holdings Inc. TO:CURA	Drug Manufacturers - Specialty & Generic	3.73%
Tianjin Chase Sun Pharmaceutical Co Ltd SHE:300026	Drug Manufacturers - Specialty & Generic	-0.89%
Changzhou Qianhong Biopharma Co Ltd SHE:002550	Drug Manufacturers - Specialty & Generic	18.70%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%

LIVZON PHARMAC. GRP H YC1 Asset Resilience Ratio by Year (2021–2025)

LIVZON PHARMAC. GRP H YC1 asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for LIVZON PHARMAC. GRP H YC1.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	5.61%	€1.34 Billion ≈ $1.57 Billion	€23.99 Billion ≈ $28.04 Billion	+5.24pp
2024-12-31	0.37%	€89.36 Million ≈ $104.47 Million	€24.46 Billion ≈ $28.59 Billion	+0.04pp
2023-12-31	0.33%	€81.79 Million ≈ $95.62 Million	€25.04 Billion ≈ $29.28 Billion	-0.11pp
2022-12-31	0.43%	€108.09 Million ≈ $126.37 Million	€24.87 Billion ≈ $29.07 Billion	-0.38pp
2021-12-31	0.82%	€182.77 Million ≈ $213.68 Million	€22.37 Billion ≈ $26.16 Billion	--

pp = percentage points

About LIVZON PHARMAC. GRP H YC1

F:LP6 Germany Drug Manufacturers - Specialty & Generic

Market Cap

$883.28 Million

€755.51 Million EUR

Market Cap Rank

#9118 Global

#1167 in Germany

Share Price

€2.52

Change (1 day)

-0.79%

52-Week Range

€2.08 - €3.54

All Time High

€4.30